EDX Medical Group plc (AIM: EDX), the Cambridge-based digital diagnostics company, has disclosed that its founder, board director and Chief Scientific Officer, Professor Sir Christopher Evans OBE, purchased 197,500 ordinary shares in the company via open market trading on 6 and 9 November 2026 at an average price of 7.5 pence per share. The transaction, reported in accordance with UK Market Abuse Regulation requirements, increases Professor Evans's total holding to 136,417,793 shares, representing 31.62% of the issued share capital. Director share purchases are closely watched by investors as a potential signal of insider confidence in a company's prospects.

Key Points

  • EDX Medical Group plc (AIM: EDX), Cambridge-based digital diagnostics developer
  • Founder and Chief Scientific Officer Professor Sir Christopher Evans OBE purchased 197,500 ordinary shares on the open market on 6 and 9 November 2026
  • Shares acquired at an average price of 7.5 pence per share; Professor Evans now holds 31.62% of issued share capital
  • Investors may be watching whether further director purchases follow or whether the company issues any operational updates

Professor Sir Christopher Evans Acquires Shares Across Two Trading Days at 7.5p

According to the regulatory notification, Professor Evans completed purchases across two separate dates: 67,500 shares were acquired at £0.074 on 6 November 2026, with a further 65,000 shares purchased at £0.075 and an additional 65,000 shares at £0.075 on 9 November 2026. The transactions were executed on the AIM market through the London Stock Exchange. All shares are ordinary shares of £0.01 each, carrying ISIN reference GB00BNDMJS47. The announcement was made as an initial notification under Article 19(1) of the EU Market Abuse Regulation as incorporated into UK law.

Evans's Stake Rises to 31.62% Following Latest Purchase in EDX Medical

Following these transactions, Professor Evans now holds 136,417,793 ordinary shares in EDX Medical Group, equating to 31.62% of the company's issued share capital, making him a highly significant shareholder. Professor Evans co-founded EDX Medical alongside Chief Executive Officer Dr Mike Hudson. With more than 30 years of experience as a medical and life sciences entrepreneur, Evans also serves as the company's Chief Scientific Officer, combining a strategic and scientific leadership role with this substantial ownership position.

EDX Medical's Cambridge Diagnostics Business and Strategic Partnerships

EDX Medical Group develops and supplies digital diagnostic products and services aimed at improving the early detection and treatment of major diseases. Operating its own facilities in Cambridge, UK, the company provides doctors, hospitals and insurers with access to a portfolio of clinical diagnostics products and services. EDX Medical holds a strategic product and technology partnership with Thermo Fisher EMEA Ltd, a global leader in life sciences solutions. The company's model focuses on combining advanced biological and digital technologies to personalise treatment and improve patient outcomes cost-effectively.

Nominated Adviser Canaccord Genuity Supports AIM-Listed EDX Medical

Canaccord Genuity Limited acts as nominated adviser and broker to EDX Medical Group on AIM. Investor relations are handled by IFC Advisory, while media enquiries are managed by Media House International. The company's CEO Dr Mike Hudson is listed as the primary contact for corporate enquiries. EDX Medical did not issue any operational update or forward guidance alongside this director dealing notification. Investors may be watching for further announcements regarding the company's diagnostics pipeline or commercial partnerships in the period ahead.